BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37918013)

  • 21. KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.
    Formica V; Sera F; Cremolini C; Riondino S; Morelli C; Arkenau HT; Roselli M
    J Natl Cancer Inst; 2022 Apr; 114(4):517-527. PubMed ID: 34542636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of inflammatory parameters in predicting disease recurrence in patients with stage IIA colon cancer with no high-risk features.
    Erdur E; Yildirim OA; Poyraz K; Aslan F; Yıldız F; Kömek H
    Postgrad Med; 2021 Aug; 133(6):694-700. PubMed ID: 34030576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
    Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
    Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation.
    Ali MAM; Harmsen WS; Morsy KH; Galal GMK; Therneau TM; Roberts LR
    BMC Cancer; 2022 Feb; 22(1):221. PubMed ID: 35227234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
    Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J
    Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
    Bennedsen ALB; Cai L; Hasselager RP; Özcan AA; Mohamed KB; Eriksen JO; Eiholm S; Bzorek M; Fiehn AK; Hviid TVF; Gögenur I
    BMC Cancer; 2022 Jan; 22(1):62. PubMed ID: 35027037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
    Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
    Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors and Differences in Survival of Right and Left Colon Carcinoma: A STROBE Compliant Retrospective Cohort Study.
    Beltrán L; González-Trejo S; Carmona-Herrera DD; Carrillo JF; Herrera-Goepfert R; Aiello-Crocifoglio V; Gallardo-Rincón D; Meléndez-Ponce NA; Ochoa-Carrillo FJ; Oñate-Ocaña LF
    Arch Med Res; 2019 Feb; 50(2):63-70. PubMed ID: 31349955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perineural Invasion Is a Prognostic but not a Predictive Factor in Nonmetastatic Colon Cancer.
    Leijssen LGJ; Dinaux AM; Taylor MS; Deshpande V; Kunitake H; Bordeianou LG; Berger DL
    Dis Colon Rectum; 2019 Oct; 62(10):1212-1221. PubMed ID: 31490830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
    Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
    Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer.
    Suzuki S; Akiyoshi T; Oba K; Otsuka F; Tominaga T; Nagasaki T; Fukunaga Y; Ueno M
    Ann Surg Oncol; 2020 Mar; 27(3):844-852. PubMed ID: 31720937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.
    Brungs D; Aghmesheh M; de Souza P; Ng W; Chua W; Carolan M; Clingan P; Healey E; Rose J; Tubaro T; Ranson M
    BMC Cancer; 2017 Apr; 17(1):251. PubMed ID: 28390415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.